AMGN - Comprehensive Filing Intelligence

FY•10-K•Filed Feb 13, 2026
6.0/10
Filing Health:GOOD

Solid fundamentals with minor concerns to monitor

Executive Summary

Total product sales grew 10% in 2025, driven by strong volume growth (13%), though partially offset by a 3% decline in net selling price.. Operating expenses increased 6% due to investments in clinical programs and impairment charges, impacting margins.. Significant purchase obligations of $6.9 billion are noted for R&D, capital expenditures, and operational needs, with most due within a year.. Total revenue growth of 14.7% in 2025.

Top Concerns

  • !Total product sales grew 10% in 2025, driven by strong volume growth (13%), though partially offset by a 3% decline in net selling price.
  • !Significant purchase obligations of $6.9 billion are noted for R&D, capital expenditures, and operational needs, with most due within a year.
  • !There is a substantial potential future liability of $7.2 billion tied to contingent milestone payments for third-party agreements, which carry high uncertainty.
  • !Regulatory Compliance and Product Approval (high)
  • !Competition from Biosimilars and Generics (high)

Top Positives

  • +Total product sales grew 10% in 2025, driven by strong volume growth (13%), though partially offset by a 3% decline in net selling price.
  • +Operating expenses increased 6% due to investments in clinical programs and impairment charges, impacting margins.
  • +The company generated strong operating cash flow ($10.0 billion) which was used for debt reduction, capital expenditures, and shareholder returns.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is confidently optimistic with focus on lower amortization expense from acquisition-related assets, including the fair value step-up of inventory acquired from horizon.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is low with $14.1 billion in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows regulatory compliance and product approval as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

7.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.

Related Research

Analysis

AMGN 10-K Analysis: Net Income Doubled While Cash Flow Fell 13%

Analysis

PFE 10-K Analysis: The Dual Depletion Hiding in Pfizer's Balance Sheet

Analysis

GILD 10-K Analysis: The $636M Pricing Gap Wall Street Hasn't Quantified